Clinical TrialsPositive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.
Intellectual PropertyAtossa bolstered its intellectual property portfolio with new patents for endoxifen, strengthening its market position.
Market PotentialThe market potential of approximately a billion dollars presents high rewards for these risks.
ValuationThe current valuation is considered attractive, maintaining a BUY rating and raising the 12-month price target to $7.50, indicating significant upside potential.